Effect of dexmedetomidine on myocardial ischemia-reperfusion injury
Shoulin Chen, Fuzhou Hua, Jun Lu, Yu Jiang, Yanhua Tang, Lei Tao, Bing Zou, Qinghua Wu, Shoulin Chen, Fuzhou Hua, Jun Lu, Yu Jiang, Yanhua Tang, Lei Tao, Bing Zou, Qinghua Wu
Abstract
Cardiopulmonary bypass (CPB) is associated with a marked systemic inflammatory response. Although dexmedetomidine (Dex) is routinely used in cardiac surgery, the effect in reducing the inflammatory response in coronary artery bypass graft surgery (CABG) with CPB remains unclear. In this study, Dex was administered at a loading dose of 0.5 μg/kg for 10 min, followed by a continuous infusion of 0.5 μg/kg per hour until the completion of CABG with CPB. The levels of inflammatory cytokines in the serum, including tumor necrosis factor-alpha (TNFalpha), interleukin (IL)-6, IL-8 and IL-10, were measured to explore the inflammatory regulating function of Dex. In addition, troponin-I (cTnI) and creatine kinase (CK-MB) levels were studied to explore the myocardial protection provided by Dex. In this study, we showed Dex inhibited the increase in cTnI and CK-MB, attenuated the production of pro-inflammatory cytokines TNF-alpha, IL-6 and IL-8, and promoted anti-inflammatory cytokine IL-10 production. These findings demonstrate that Dex regulates anti-inflammatory as well as myocardial protection potential in CABG with CPB.
Keywords: Dexmedetomidine; coronary artery bypass grafting; inflammatory response; myocardial injury.
Figures
![Figure 1](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/4723895/bin/ijcem0008-21166-f1.jpg)
Figure 2
Concentrations of pro-inflammatory cytokines (TNF-alpha-panel…
Figure 2
Concentrations of pro-inflammatory cytokines (TNF-alpha-panel A, IL-6-panel B, IL-8-panel C) and anti-inflammatory cytokine…
- Effects of Pre-Cardiopulmonary Bypass Administration of Dexmedetomidine on Cardiac Injuries and the Inflammatory Response in Valve Replacement Surgery With a Sevoflurane Postconditioning Protocol: A Pilot Study.Zhou H, Zhou D, Lu J, Wu C, Zhu Z. Zhou H, et al. J Cardiovasc Pharmacol. 2019 Aug;74(2):91-97. doi: 10.1097/FJC.0000000000000698. J Cardiovasc Pharmacol. 2019. PMID: 31356535 Free PMC article. Clinical Trial.
- Dexmedetomidine decreases the inflammatory response to myocardial surgery under mini-cardiopulmonary bypass.Bulow NM, Colpo E, Pereira RP, Correa EF, Waczuk EP, Duarte MF, Rocha JB. Bulow NM, et al. Braz J Med Biol Res. 2016;49(4):e4646. doi: 10.1590/1414-431X20154646. Epub 2016 Feb 23. Braz J Med Biol Res. 2016. PMID: 26909786 Free PMC article. Clinical Trial.
- Dexmedetomidine-induced cardioprotection is mediated by inhibition of high mobility group box-1 and the cholinergic anti-inflammatory pathway in myocardial ischemia-reperfusion injury.Zhang J, Xia F, Zhao H, Peng K, Liu H, Meng X, Chen C, Ji F. Zhang J, et al. PLoS One. 2019 Jul 25;14(7):e0218726. doi: 10.1371/journal.pone.0218726. eCollection 2019. PLoS One. 2019. PMID: 31344138 Free PMC article.
- Cytokines in myocardial injury: impact on cardiac surgical approach.Wan S, Yim AP. Wan S, et al. Eur J Cardiothorac Surg. 1999 Sep;16 Suppl 1:S107-11. doi: 10.1016/s1010-7940(99)00200-6. Eur J Cardiothorac Surg. 1999. PMID: 10536961 Review.
- Myocardial protective and anti-inflammatory effects of dexmedetomidine in patients undergoing cardiovascular surgery with cardiopulmonary bypass: a systematic review and meta-analysis.Chen M, Li X, Mu G. Chen M, et al. J Anesth. 2022 Feb;36(1):5-16. doi: 10.1007/s00540-021-02982-0. Epub 2021 Aug 3. J Anesth. 2022. PMID: 34342722 Free PMC article. Review.
- Efficacy of dexmedetomidine on myocardial ischemia/reperfusion injury in patients undergoing cardiac surgery with cardiopulmonary bypass: A protocol for systematic review and meta-analysis.Liang G, Li Y, Li S, Huang Z. Liang G, et al. Medicine (Baltimore). 2023 Mar 3;102(9):e33025. doi: 10.1097/MD.0000000000033025. Medicine (Baltimore). 2023. PMID: 36862913 Free PMC article.
- Influence of Dexmedetomidine on Myocardial Injury in Patients with Simultaneous Pancreas-Kidney Transplantation.Dong A, Zhang Y, Lu S, Yu W. Dong A, et al. Evid Based Complement Alternat Med. 2022 Nov 17;2022:7196449. doi: 10.1155/2022/7196449. eCollection 2022. Evid Based Complement Alternat Med. 2022. PMID: 36437830 Free PMC article.
- The Protective Effect of Interval Exercise on Myocardial Ischemia-Reperfusion Injury in Players.Wang W. Wang W. Biomed Res Int. 2022 Aug 8;2022:4353340. doi: 10.1155/2022/4353340. eCollection 2022. Biomed Res Int. 2022. PMID: 35978627 Free PMC article.
- Does Dexmedetomidine Reduce the Risk of Atrial Fibrillation and Stroke After Adult Cardiac Surgery? A Systematic Review and Meta-analysis of Randomized Controlled Trials.Jing C, Lin L, Zhou T, Li YL, Fu L, Gao MQ. Jing C, et al. Anatol J Cardiol. 2022 May;26(5):354-365. doi: 10.5152/AnatolJCardiol.2022.1346. Anatol J Cardiol. 2022. PMID: 35552171 Free PMC article.
- Long non-coding RNA muscleblind like splicing regulator 1 antisense RNA 1 (LncRNA MBNL1-AS1) promotes the progression of acute myocardial infarction by regulating the microRNA-132-3p/SRY-related high-mobility-group box 4 (SOX4) axis.Liu W, Lin W, Yu L. Liu W, et al. Bioengineered. 2022 Jan;13(1):1424-1435. doi: 10.1080/21655979.2021.2018974. Bioengineered. 2022. PMID: 34978261 Free PMC article.
- Full Text Sources
- Medical
- Research Materials
- Miscellaneous
![Figure 2](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/4723895/bin/ijcem0008-21166-f2.jpg)
Source: PubMed